S&P 500   3,755.81 (-2.44%)
DOW   30,334.65 (-1.95%)
QQQ   321.10 (-2.28%)
AAPL   142.19 (-0.68%)
MSFT   232.40 (+0.03%)
FB   272.97 (-3.22%)
GOOGL   1,824.41 (-4.38%)
AMZN   3,258.50 (-2.03%)
TSLA   875.32 (-0.88%)
NVDA   517.88 (-3.63%)
BABA   261.98 (-1.48%)
CGC   38.05 (+7.12%)
GE   10.78 (-4.52%)
MU   75.51 (-5.03%)
AMD   89.35 (-5.66%)
NIO   57.62 (-4.46%)
T   29.09 (-2.22%)
F   10.81 (-3.40%)
ACB   11.46 (+7.40%)
BA   193.30 (-4.34%)
DIS   162.97 (-3.89%)
NFLX   533.11 (-5.13%)
GILD   65.66 (-1.56%)
S&P 500   3,755.81 (-2.44%)
DOW   30,334.65 (-1.95%)
QQQ   321.10 (-2.28%)
AAPL   142.19 (-0.68%)
MSFT   232.40 (+0.03%)
FB   272.97 (-3.22%)
GOOGL   1,824.41 (-4.38%)
AMZN   3,258.50 (-2.03%)
TSLA   875.32 (-0.88%)
NVDA   517.88 (-3.63%)
BABA   261.98 (-1.48%)
CGC   38.05 (+7.12%)
GE   10.78 (-4.52%)
MU   75.51 (-5.03%)
AMD   89.35 (-5.66%)
NIO   57.62 (-4.46%)
T   29.09 (-2.22%)
F   10.81 (-3.40%)
ACB   11.46 (+7.40%)
BA   193.30 (-4.34%)
DIS   162.97 (-3.89%)
NFLX   533.11 (-5.13%)
GILD   65.66 (-1.56%)
S&P 500   3,755.81 (-2.44%)
DOW   30,334.65 (-1.95%)
QQQ   321.10 (-2.28%)
AAPL   142.19 (-0.68%)
MSFT   232.40 (+0.03%)
FB   272.97 (-3.22%)
GOOGL   1,824.41 (-4.38%)
AMZN   3,258.50 (-2.03%)
TSLA   875.32 (-0.88%)
NVDA   517.88 (-3.63%)
BABA   261.98 (-1.48%)
CGC   38.05 (+7.12%)
GE   10.78 (-4.52%)
MU   75.51 (-5.03%)
AMD   89.35 (-5.66%)
NIO   57.62 (-4.46%)
T   29.09 (-2.22%)
F   10.81 (-3.40%)
ACB   11.46 (+7.40%)
BA   193.30 (-4.34%)
DIS   162.97 (-3.89%)
NFLX   533.11 (-5.13%)
GILD   65.66 (-1.56%)
S&P 500   3,755.81 (-2.44%)
DOW   30,334.65 (-1.95%)
QQQ   321.10 (-2.28%)
AAPL   142.19 (-0.68%)
MSFT   232.40 (+0.03%)
FB   272.97 (-3.22%)
GOOGL   1,824.41 (-4.38%)
AMZN   3,258.50 (-2.03%)
TSLA   875.32 (-0.88%)
NVDA   517.88 (-3.63%)
BABA   261.98 (-1.48%)
CGC   38.05 (+7.12%)
GE   10.78 (-4.52%)
MU   75.51 (-5.03%)
AMD   89.35 (-5.66%)
NIO   57.62 (-4.46%)
T   29.09 (-2.22%)
F   10.81 (-3.40%)
ACB   11.46 (+7.40%)
BA   193.30 (-4.34%)
DIS   162.97 (-3.89%)
NFLX   533.11 (-5.13%)
GILD   65.66 (-1.56%)
Log in
NASDAQ:BFRA

Biofrontera Stock Forecast, Price & News

$7.82
-0.02 (-0.26 %)
(As of 01/27/2021 02:18 PM ET)
Add
Compare
Today's Range
$7.61
Now: $7.82
$7.82
50-Day Range
$6.75
MA: $7.52
$8.57
52-Week Range
$5.27
Now: $7.82
$55.00
Volume1,101 shs
Average Volume103,709 shs
Market Capitalization$186.69 million
P/E RatioN/A
Dividend YieldN/A
Beta1.25
Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the-counter line of skin care cosmetic products. In addition, it is developing Ameluz for the treatment of field cancerization and nodular basal cell carcinoma; BF-derm1 for the treatment of chronic and antihistamine-resistant urticaria; and BF-1 for the prophylactic treatment of migraine. Further, the company's product portfolio includes Xepi, a prescription antibiotic cream for the treatment of impetigo; and Aktipak, a generic drug for the treatment of acne. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.
Biofrontera logo

MarketRank

Overall MarketRank

1.00 out of 5 stars

Medical Sector

968th out of 1,926 stocks

Pharmaceutical Preparations Industry

472nd out of 772 stocks

Analyst Opinion: 2.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BFRA
CUSIPN/A
CIKN/A
Phone011-49-2148-7600
Employees174
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$35.02 million
Book Value$0.50 per share

Profitability

Net Income$-8,240,000.00

Miscellaneous

Market Cap$186.69 million
Next Earnings Date4/19/2021 (Estimated)
OptionableNot Optionable
$7.82
-0.02 (-0.26 %)
(As of 01/27/2021 02:18 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BFRA News and Ratings via Email

Sign-up to receive the latest news and ratings for BFRA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Biofrontera (NASDAQ:BFRA) Frequently Asked Questions

How has Biofrontera's stock been impacted by Coronavirus (COVID-19)?

Biofrontera's stock was trading at $9.28 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BFRA shares have decreased by 16.5% and is now trading at $7.75.
View which stocks have been most impacted by COVID-19
.

Is Biofrontera a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biofrontera in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Biofrontera stock.
View analyst ratings for Biofrontera
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Biofrontera?

Wall Street analysts have given Biofrontera a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Biofrontera wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Biofrontera's next earnings date?

Biofrontera is scheduled to release its next quarterly earnings announcement on Monday, April 19th 2021.
View our earnings forecast for Biofrontera
.

How were Biofrontera's earnings last quarter?

Biofrontera AG (NASDAQ:BFRA) posted its quarterly earnings results on Monday, November, 16th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.06. The business had revenue of $5.51 million for the quarter. Biofrontera had a negative net margin of 46.87% and a negative trailing twelve-month return on equity of 348.25%.
View Biofrontera's earnings history
.

How often does Biofrontera pay dividends? What is the dividend yield for Biofrontera?

Biofrontera announced a -- dividend on Wednesday, March 18th. Shareholders of record on Thursday, March 19th will be paid a dividend of $0.0221 per share on Monday, March 30th. The ex-dividend date is Wednesday, March 18th.
View Biofrontera's dividend history
.

What guidance has Biofrontera issued on next quarter's earnings?

Biofrontera updated its FY 2020 IntraDay earnings guidance on Friday, January, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $37.269-37.638 million, compared to the consensus revenue estimate of $34.3 million.

What price target have analysts set for BFRA?

2 brokers have issued 1 year price targets for Biofrontera's stock. Their forecasts range from $8.00 to $11.00. On average, they expect Biofrontera's stock price to reach $9.50 in the next year. This suggests a possible upside of 22.6% from the stock's current price.
View analysts' price targets for Biofrontera
or view Wall Street analyst' top-rated stocks.

Who are some of Biofrontera's key competitors?

What other stocks do shareholders of Biofrontera own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biofrontera investors own include AbbVie (ABBV), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Adaptimmune Therapeutics (ADAP), (AZN), GW Pharmaceuticals (GWPH), Pfizer (PFE), Alnylam Pharmaceuticals (ALNY) and Ascendis Pharma A/S (ASND).

Who are Biofrontera's key executives?

Biofrontera's management team includes the following people:
  • Dr. Hermann Lübbert, Co-Founder, Chairman of the Exec. Board & CEO (Age 64)
  • Mr. Thomas Schaffer, CFO & Member of the Exec. Board (Age 57)
  • Pamela Keck, Head of Investor Relations
  • Mr. Alexander Richardson, Head of UK Sales Team
  • Dr. Matthias Naumann, Head of Sales & Marketing - Europe

When did Biofrontera IPO?

(BFRA) raised $18 million in an IPO on Wednesday, February 14th 2018. The company issued 1,500,000 shares at $11.00-$13.00 per share. Benchmark served as the underwriter for the IPO and Dawson James Securities and Lake Street Capital Markets were co-managers.

What is Biofrontera's stock symbol?

Biofrontera trades on the NASDAQ under the ticker symbol "BFRA."

How do I buy shares of Biofrontera?

Shares of BFRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Biofrontera's stock price today?

One share of BFRA stock can currently be purchased for approximately $7.75.

How big of a company is Biofrontera?

Biofrontera has a market capitalization of $185.02 million and generates $35.02 million in revenue each year. Biofrontera employs 174 workers across the globe.

What is Biofrontera's official website?

The official website for Biofrontera is www.biofrontera.com.

How can I contact Biofrontera?

Biofrontera's mailing address is HEMMELRATHER WEG 201, LEVERKUSEN 2M, D-51377. The company can be reached via phone at 011-49-2148-7600 or via email at [email protected]

This page was last updated on 1/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.